NASVAX LTD
NasVax developed a platform technology that enable existing commercial vaccines to be administered intranasal.
NASVAX LTD
Industry:
Health Care Information Technology Medical
Address:
Rehovot, HaMerkaz, Israel
Country:
Israel
Status:
Active
More informations about "NasVax Ltd"
NasVax Ltd - Crunchbase Company Profile & Funding
NasVax Ltd is located in Rehovot, HaMerkaz, Israel. Who are NasVax Ltd's competitors? Alternatives and possible competitors to NasVax Ltd may include Wecare247 and Delawave. …See details»
Nasvax - LinkedIn
NasVax develops improved vaccines and immunotherapeutic products. The company has four distinct product areas: i. oral anti-CD3 monoclonal antibody immunotherapeutic; ii.See details»
Erez Chimovits - CEO - NasVax Ltd. | LinkedIn
CEO at NasVax Ltd. · Experience: NasVax Ltd. · Location: San Jose · 112 connections on LinkedIn. View Erez Chimovits’ profile on LinkedIn, a professional community of 1 billion …See details»
Terms of Reference - World Health Organization (WHO)
DECLARATION OF INTERESTS FOR WHO EXPERTS - World Health …
Her university receives funding from Sanofi Pasteur, NasVax Ltd and DBV Technologies for conducting research in vaccine adjuvants and seroepidemiology of pneumococcal infections. …See details»
Novartis to Evaluate NasVax Adjuvant Technology
Feb 22, 2010 · NasVax entered into a joint research and option for license agreement with Novartis Vaccines and Diagnostics to investigate the feasibility of developing improved …See details»
NasVax Ltd - Tech Stack, Apps, Patents & Trademarks - Crunchbase
NasVax developed a platform technology that enable existing commercial vaccines to be administered intranasal.See details»
NasVax Ltd. :: Scrip
Jan 1, 2008 · NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family …See details»
NasVax Ltd. :: Pink Sheet
Jan 1, 2008 · NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family …See details»
NasVax Announces Presentation at Biotech Showcase and J.P.
Jan 10, 2011 · NasVax develops improved vaccines and immunotherapeutic products. The company has four distinct product development programs. Oral anti-CD3 immunotherapy …See details»
NasVax Ltd. - insights.citeline.com
May 1, 2007 · NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family …See details»
NasVax says inks vaccine research deal with Novartis | Reuters
Feb 21, 2010 · Israel's NasVax Ltd
Israeli firm reports positive trials of H1N1 vaccine | Reuters
JERUSALEM, Oct 13 (Reuters) - Israeli vaccine maker NasVax Ltd reported on Tuesday positive results of preclinical trials of its vaccine against the H1N1 flu strain.See details»
Nasvax Advances Most in Three Months on Trial of Liver Treatment
Mar 21, 2011 · Nasvax Ltd. rose the most in almost three months after its parent company Biomedix Incubator Ltd. said Nasvax’s Phase 2a clinical trial of a treatment for fatty liver was …See details»
NasVax Ltd. :: In Vivo
Jan 1, 2008 · NasVax Ltd.'s VaxiSome, a novel adjuvant/delivery system for enhacing the activity of existing vaccines, consists of lipid assemblies comprising an innovative, proprietary family …See details»
NasVax Initiates Phase 2a Clinical Trial for Oral Anti-CD3 …
Sep 20, 2010 · NasVax develops improved vaccines and immunotherapeutic products. The company has four product development programs. The aCD3 oral immunotherapy program …See details»
Mucosal Vaccine Development Based on Liposome Technology
The main inductive sites for mucosal immune responses after intranasal vaccination are known as nasopharynx-associated lymphoid tissue (NALT), which harbors B cell follicles and T cell …See details»
Oral Administration of OKT3 MAb to Patients with NASH
Apr 17, 2015 · Oral administration of anti-CD3 antibodies induced regulatory T cells (Tregs) alleviating the insulin resistance and liver damage in animal models. To determine the safety …See details»
How the Novavax COVID-19 vaccine differs from those already
Feb 2, 2021 · Novavax is still conducting clinical trials, but if Health Canada approves the vaccine, a new National Research Council-owned facility in Montreal will begin pumping out doses …See details»
How Montreal could lead the way to Canada's first domestically …
Nov 4, 2021 · With Novavax filing for approval of its vaccine with Health Canada, Montreal is poised to be the first Canadian city to manufacture a COVID-19 vaccine, though domestically …See details»